Blood collection and overview (routine) measurements

Blood collection and overview (routine) measurements

LASA file name(s):
LASAB850 / LASAC850 / LAS2B850 / LASAG850 / LAS3B850: Response blood sampling / DNA
LASAB851 / LASAC851 / LAS2B851 / LASAG851 / LAS3B851: Date blood sampling (including time point when available)
LASAB860 / LASAC860 / LAS2B860 / LASAG860 / LAS3B860: Routine measurements

Contact: Natasja van Schoor

Blood collection first cohort (B-, C- and G-cycle)

At the LASA B-cycle (1992/93), blood was collected in the regions Amsterdam and Zwolle; no blood was collected in Oss. Non-fasting blood samples were taken during the medical interview while the subject was sitting. The blood that was obtained during this cycle was centrifuged and stored at -80° until determination. Several routine determinations were performed immediately, this concerns blood of the region Zwolle and part of the region Amsterdam (Table 5). In the region Zwolle this was done in the ISALA clinic; in Amsterdam this was done in the PCA Valeriuskliniek. See Table 1 for the response rates.

At the LASA C-cycle (1995/96), blood samples were obtained from respondents who participated in the medical interview of LASA (1995/96), were born in 1930 and before (aged 65 years and older as of 1 January, 1996) and were living in Amsterdam, Zwolle and Oss and surroundings. Of the 1,720 respondents who were eligible for the medical interview, 1,509 took part in the medical interview. After this interview at home, participants were invited to the VUmc (respondents living in Amsterdam and vicinity) or a health care center near their homes (respondents living in Zwolle or Oss and vicinity), where blood samples were obtained. For respondents who were not able to come to the VUmc, blood samples were drawn at home (n=76). Blood samples were available for 1,331 respondents. At the visit in the hospital or health care center, fasting urine and blood samples were obtained, centrifuged and stored at -80° or analyzed immediately. In the region Zwolle the immediate assays were done in the ISALA clinic; in Amsterdam this was done in the VUmc; in Oss, this was done in the Bernhoven Hospital. Respondents were allowed to take tea and toast, but no dairy products. In Amsterdam, morning blood samples were collected (between 8.30 and 9.30 a.m.); in Zwolle, blood samples were collected during the daytime; in Oss, morning blood samples were collected (between 8.00 and 10.00 a.m.).. See Table 1 for the response rates.
At the LASA G-cycle (2008/09), fasting blood samples were drawn in Amsterdam, Zwolle and Oss and surroundings. Subjects were not allowed to take any food or drinks from midnight. Of 58 respondents, blood samples were drawn at home. The other participants were sampled on location. The samples were centrifuged and stored at -80° or analyzed immediately. See Table 1 for the response rates.


In general:

Blood sampling took place within 4 to 6 weeks after the medical interview of LASA, except for the B-cycle where blood sampling took place at home during the medical interview. Routine determinations were performed immediately after blood sampling in the lab where the blood was collected (in case of using health care centers near the home of a respondent, or home visit, the blood was transported to the central laboratory of each region). Samples were centrifuged within 4 hours. It should be noted that different labs were used in the different regions. Furthermore, when comparing routine measurements performed in fresh blood over time, it should be noted that at the B-cycle a different laboratory was used in Amsterdam (PCA Valeriuskliniek) than at later cycles (VUmc). All blood samples are stored at -80°. However, in case of a new determination in blood, the blood is temporarily stored at the laboratory at -20°.

Laboratory determination

Albumin, creatinine and total cholesterol were determined as routine measurements in fresh blood at LASA B and C; fasting glucose was additionally assessed at LASA G. For an overview of the most important biomaterial measurements, see Table 4. For a detailed overview of routine measurements, see Table 5.

Table 1. Response first cohort

Cycle Total medical interview Number of blood samples Response (%)
B1 2675 (2671)2 17843 66.7
C 1509 1331 88.2
G4 761 400 52.6

1 No blood was collected in Oss in the B-cycle.
2 In 4 persons, data of the medical interview were lost.
3 In part of Amsterdam blood was collected but routine measurements were not determined immediately (n=502) in the B-cycle.
4 At the G-cycle, a combined blood collection was performed in the first and second cohort. Reported numbers include only the first cohort.

Blood collection second cohort (2B- and G-cycle)

At the LASA 2B cycle (2002/03), blood samples were collected in Amsterdam, Zwolle and Oss and surroundings. Respondents were allowed to take tea and toast, but no dairy products. In Amsterdam, morning blood samples were collected (between 8.30 and 9.30 a.m.); in Zwolle, blood samples were collected during daytime; in Oss, morning blood samples were collected (between 8.00 and 10.00 a.m.). Of 15 participants, blood samples were drawn at home. The other participants were sampled on location. The samples were centrifuged and stored at -80° or analyzed immediately. See Table 2 for the response rates.

At the LASA G-cycle (2008/09), fasting blood samples were drawn in Amsterdam, Zwolle Oss and surroundings. Subjects were not allowed to take any food or drinks from midnight. Of 11 participants, blood samples were drawn at home. The other participants were sampled on location. The samples were centrifuged and stored at -80° or analyzed immediately. See Table 2 for the response rates.

Laboratory determination

Albumin, creatinine and total cholesterol were determined as routine measurements in fresh blood at LASA 2B; fasting glucose was additionally assessed at LASA G. For an overview of the most important biomaterial measurements, see Table 4. For a detailed overview of routine measurements, see Table 5.

Table 2. Response second cohort

Cycle Total medical interview Number of blood samples Response (%)
2B 919 748 81.4
G1 733 535 73.1

1 At the G-cycle, a combined blood collection was performed in the first and second cohort. Reported numbers include only the second cohort.

Blood collection third cohort (3B cycle)

At the 3B-cycle (2012/13), fasting blood samples were drawn. Subjects were not allowed to take any food or drinks from midnight. The samples were centrifuged and stored at -80° or analyzed immediately. See Table 3, for the response rates.

Laboratory determination

Fasting glucose was assessed as a routine measurement in fresh blood (Table 4).

Table 3. Response third cohort

Cycle Total medical interview Number of blood samples Response (%)
3B 889 TBD TBD

TBD=To be determined

Table 4. Most important biomaterial measurements and realized sample size (see also the European Journal of Epidemiology 2016)

Biomaterial Availability
in LASA (n)
Routine measurements in fresh blood B C 2B G 3B
Albumin 1507 1326 747 924
Creatinine 1507 1327 747 925
Total cholesterol 1507 1309 744 923
Fasting glucose 918 640
Measurements in frozen blood a B C 2B G 3B b
Total cholesterol 1296
Creatinine 632
High-density lipoprotein (HDL) cholesterol 1295
Low-density lipoprotein (LDL) cholesterol 1287
Triglycerides 1296
Fructosamine 1298
Adipokines (adiponectin, leptin, ghrelin) 897
Total plasma cortisol 1279
Cortisol binding globulin (CBG) 1277
Homocysteine 1301
Vitamin B12 1276
Methylmalonic acid (MMA) 582
Sex hormone-binding globulin (SHBG) 1320
Insulin-like growth factor 1 (IGF-1) 1319
Osteocalcin (OC) 1319
Pro-inflammatory cytokine Interleukin-6 (IL-6) 1745 1287 638
Acute-phase proteins C-reactive protein (CRP) 1744 1287 631
Alpha-1-antichymotrypsin (ACT) 1743 1284
Serum 25-hydroxyvitamin D (25-OHD) 1320 739 916 639
Parathyroid hormone (PTH) 1320 739 915
Follicle stimulating hormone (FSH) 1301
Luteinizing hormone (LH) 1301
Testosterone 630
Estradiol 1301
Thyroid stimulating hormone (TSH) c 1270
Vitamin K (dp-ucMGP + dp-cMGP) 696
Other measurements C E Ancillary study
(2010-11)
Urine deoxypyridinolin (DPD) 1307
Urine creatinine 1311
Salivary cortisol 1199
Hair cortisol 333
DNA First cohort Second cohort Third cohort
Exome chip analysis 1193 NYAa
Apolipoprotein E (ApoE) phenotyping 2233
Apolipoprotein E (ApoE) genotyping 753
Collagen type I α1 Sp1 polymorphism 966
Single nucleotide polymorphisms Vitamin D Receptor 935
Single nucleotide polymorphisms Glucocorticoid Receptor 935

a NYA=Not yet available. New blood determinations may become available in the future from frozen blood.
b Partly available: Blood has been collected (n = 640), but not all assessments have been performed yet.
c In case of abnormalities in TSH level, Tri-jodothyronin (T3) and/or Thyroxin (T4) were measured.

Table 5. Detailed overview of routine measurements in fresh blood in first and second cohort
a

First cohort Second cohort
B-cycle (n=2675) C-cycle (n=1509) G-cycle (n=761) 2B-cycle(n=919) G-cycle (n=733)
  N= valid data N= valid data N= valid data N= valid data N= valid data
Haemoglobine mMol/L 1509 400 282
Haematocriet LL 1508 400 280
Erythrocyten x(10 power 12)/L 1508 400 280
Leucocyten x(10 power 9)/L 1494 398 280
Multi cellulair hamoglobine a Mol 736
Multi cellulair volume FL 736
Multi cellulair haemoglobine concentration mMol/L 736
Creatinine uMol/L 1507 1327 395 747 530
Albumine g/L 1507 1326 395 747 529
Total cholesterol mMol/L 1507 1309 395 744 528
Cholesterol/HDL ratio 1502 404 283
Ferro uMol/L 773 404 283
Vitamine B12 pMol/L 767 404 283
Foliumacid nMol/L 772 400 283
TSH mU/L 769 398 283
CRP mG/L 223 404 283
Calcium mMol/L 773 404 283
Ureum mMol/L 773 404 283
Total Protein G/L 773 404 283
OT (ASAT) U/L 773 404 283
PT (ASAT) U/L 773 404 283
Gamma GT U/L 773 404 283
Glucose mMol/L 773 404 391 283 527
Triglyceriden mMol/L 773 404 283
HDL mMol/L 770 404 283
Free T4 pMol/L 773 404 283
LDL mmol/L 768 404 283
BSE mm/U 1505 398 276

a Not necessarily performed in same selection of participants.

Date of last update: April 22, 2020